# Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

> **NCT07663253** · — · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 333 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07663253
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-02
- **Final completion:** 2030-09
- **Target enrollment:** 333 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663253, "Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07663253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*